Generative AI (GenAI) is transforming how competition-related cases, including merger control and investigations, are handled. Its ability to analyse vast amounts of data quickly and accurately is proving to be a game-changer.

The Federal real estate has long operated out of sync with the natural boom-and-bust cycles that shape the commercial real estate market. With 11.4 million square feet of leases set to expire, the federal government has an incredible opportunity to realign it’s real estate holdings to the market.

A&M Tax Managing Director Kevin M. Jacobs was recently featured in The Wall Street Journal in an article highlighting the cash savings companies are benefiting from under the new tax law.

In May 2025, Washington enacted multiple tax bills into law, including Senate Bill 5814 (SB 5814), which takes effect on October 1st and will broaden the sales and use tax base and the Business and Occupation (B&O) tax retailing classification to include several new services.

Survey highlights value creation strategies emerging trends like AI and ESG as key levers for success amid tariff and trade challenges.

The Ascent Group - A&M AUS Insolvency Portal

Griffin Coal - A&M AUS Insolvency Portal

Entyr Group - A&M AUS Insolvency Portal

The Australian private equity market is set to play a pivotal role in shaping the country’s economic future. In our inaugural Australia Private Equity Value Creation report, we deep dive into how Australian-focused PE funds and operators are performing and how their strategies compare globally.

Leading global professional services firm Alvarez & Marsal’s (A&M) Global Transaction Advisory Group (Global TAG) has
appointed Htike Htike Kyaw Soe as a Managing Director within its Global Transaction Analytics (GTA) unit.

In this article, we take a closer look at the increasing risk landscape for PE and VC firms, while outlining actionable strategies to mitigate these exposures.

Alvarez & Marsal's new Swiss Debt Restructuring Moratorium Survey reveals the number of cases peaked once again in 2024, building on the increased utilization already observed in 2023.

As biologics face a record-breaking patent cliff, the anticipated biosimilar wave may be more of a ripple than a wave. To thrive, life sciences firms must shift from solely pursuing speed to mastering precision.

This article is the first in a three-part series on hidden costs in inventory and purchasing.

As artificial intelligence matures from experimentation to enterprise deployment, one thing has become increasingly clear: there is nothing “artificial” about the intelligence required to succeed.